ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ラロトレクチニブ

Larotrectinib

HCID 46188928
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
1223403-58-4
標準SMILES
O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1
InChIKey
NYNZQNWKBKUAII-KBXCAEBGSA-N
分子式
C21H22F2N6O2
平均分子量
428.4 g/mol
単同位体質量
428.17723029

概要

Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.. On April 10, 2025, the FDA granted full drug approval.

名称と識別子

優先名称
Larotrectinib
IUPAC
(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide
現地名
ラロトレクチニブ
英語名
LOXO-101
分子式
C21H22F2N6O2
分子量
428.44

名称と別名

Larotrectinib1223403-58-4LOXO-101ARRY-470LOXO 101LOXO101ARRY 470PF9462I9HXBAY2757556BAY-2757556(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamideDTXSID101020707
名称をさらに表示
(3S)-N- [5 - [(2R)-2-(2,5-ジフルオロフェニル)-1-ピロリジニル]ピラゾロ[1,5-a]ピリミジン-3-イル] -3-ヒドロキシ-1-ピロリジンカルボキサミド(3S)-N- [5 - [(2R)-2-(2,5-ジフルオロフェニル)-1-ピロリジニル]ピラゾロ[1,5-a]ピリミジン-3-イル] -3-ヒドロキシ-1-ピロリジンカルボキサミドラロトレクチニブ(3S)-N-{5-[(2R)-2-(2,5-ジフルオロフェニル)ピロリジン-1-イル]ピラゾロ[1,5-a]ピリミジン-3-イル}-3-ヒドロキシピロリジン-1-カルボキサミド(3S)-N-[5-[(2R)-2-(2,5-ジフルオロフェニル)-1-ピロリジニル]-ピラゾロ[1,5-a]ピリミジン-3-イル]-3-ヒドロキシ-1-ピロリジンカルボアミドLarotrec(R)-N-(5-((S)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamideCS-2322LOXO 10ROM for Nepal
(3S)-N-[5-[(2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-1-pyrrolidinecarboxamide1-Pyrrolidinecarboxamide, N-[5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-, (3S)-(3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxypyrrolidine-1-carboxamide1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-larotrectinibumARRY470(3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-1-pyrrolidinecarboxamide(3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

物性

構造計算による物性

XLogP
1.7
極性表面積
86 Ų
水素結合供与体数
2
水素結合受容体数
7
回転可能結合数
3
重原子数
31
形式電荷
0
複雑度
659

実験および物理化学的性質

DrugsPharmaceuticals -> Antineoplastic and immunomodulating agents -> Antineoplastic agents
Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

物理化学的性質

比重(密度)
1.55 · 1.55±0.1 g/cm3(Predicted)
貯蔵温度
RT
溶解性
DMSO に可溶 (5 mg/ml まで)。
外見
個体
酸解離定数(Pka)
8.41 · 8.41±0.40(Predicted)
色
黄色
安定性
-20 °C · -20°C の DMSO 溶液で最大 2 か月間保存できます。

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS ClassificationNot Classified

危険有害性情報

Hazard Classes and CategoriesNot Classified

毒性情報

Hepatotoxicity · 1 件

In early clinical trials in a total of 176 patients with various forms of solid tumors which had an NTRK gene fusion, elevations in serum aminotransferase levels occurred in 45% of patients treated with larotrectinib. Serum aminotransferase levels rose to above 5 times ULN in 6% of patients and led to early discontinuation in 2%. Serum aminotransferase elevations typically arose after 4 to 12 weeks of treatment, but usually without jaundice or alkaline phosphatase elevations. Most elevations resolved within 4 to 8 weeks and discontinuations were uncommon. Restarting larotrectinib at a reduced dose after resolution of the aminotransferase abnormalities was generally well tolerated and did not lead to recurrence of liver injury. Cases with jaundice and symptoms during larotrectinib therapy have not been reported, but the clinical experience with this kinase inhibitor has been limited and prelicensure clinical trials were carried out with careful clinical monitoring.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

注意喚起語
警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302

化学と産業

薬理情報

ATC Code · 2 件

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingLarotrectinib is 70% bound to human plasma proteins _in vitro_ and binding is independent of drug concentration. The blood-to-plasma concentration ratio is 0.9.
Pharmacodynamics · 1 件

In a broad panel of purified enzyme assays, larotrectinib inhibited TRKA, TRKB, and TRKC with IC50 values between 5-11 nM. One other kinase, TNK2, was inhibited at approximately 100-fold higher concentration. At doses that are nine-fold greater than the recommended adult dose, larotrectinib does not elicit any QTc interval prolongation that is clinically relevant. No dose adjustment is recommended for patients with renal impairment of any severity, but dose reductions are warranted in patients with moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment.

Mechanism of Action · 1 件

Tropomysoin receptor kinases (TRK) like TRKA, TRKB, and TRKC elicit activities that regulate the natural growth, differentiation, and survival of neurons when they interact with endogenous neutrotrophin ligands. TRKA, TRKB, and TRKC are themselves encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively. It has been discovered that chromosomal rearrangements involving in-frame fusions of these genes with various partners, translocations in the TRK kinase domains, mutations in the TRK ligand-binding site, amplifications of NTRK, or the expression of TRK splice variants can result in constitutively-activated chimeric TRK fusion proteins that can act as oncogenic drivers that promote cell proliferation and survival in tumor cell lines. Subsequently, larotrectinib functions as an inhibitor of TRKs including TRKA, B, and C. In in vitro and in vivo tumor models, larotrectinib demonstrated anti-tumor activity in cells with constitutive activation of TRK proteins resulting from gene fusions, deletion of a protein regulatory domain, or in cells with TRK protein overexpression. Larotrectinib had minimal activity in cell lines with point mutations in the TRKA kinase domain, including the clinically identified acquired resistance mutation, G595R. Point mutations in the TRKC kinase domain with clinically identified acquired resistance to larotrectinib include G623R, G696A, and F617L.

関連反応

8 件
反応記録を作成
HRID 63998 の反応式
HRID 63998生成物として
HRID 63999 の反応式
HRID 63999反応物として
HRID 537774 の反応式
HRID 537774生成物として
HRID 537775 の反応式
HRID 537775反応物として
HRID 1893782 の反応式
HRID 1893782生成物として
HRID 1893783 の反応式
HRID 1893783反応物として
HRID 2275350 の反応式
HRID 2275350生成物として
HRID 2275351 の反応式
HRID 2275351反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
1223403-58-4
PubChem CID
46188928
DTXSID
DTXSID101020707
ChEMBL
CHEMBL3889654
UNII
PF9462I9HX
EC Number
826-190-2
Nikkaji
J3.628.138C
Biological Half-LifeIn healthy subjects, the half-life of larotrectinib following oral administration is 2.9 hours.
Metabolism/Metabolites · 1 件

Larotrectinib is metabolized predominantly by CYP3A4. Following oral administration of a single 100 mg dose of radiolabeled larotrectinib in healthy subjects, the major circulating drug components in plasma were unchanged larotrectinib (19%) and an O-linked glucuronide (26%).

FDA Pharmacological Classification · 6 件

PF9462I9HX

LAROTRECTINIB

Established Pharmacologic Class [EPC] - Kinase Inhibitor

Mechanisms of Action [MoA] - Tropomyosin Receptor Kinases Inhibitors

Larotrectinib is a Kinase Inhibitor. The mechanism of action of larotrectinib is as a Tropomyosin Receptor Kinases Inhibitor.

LAROTRECTINIB

Absorption, Distribution and Excretion · 4 件

The mean absolute bioavailability of larotrectinib capsules is approximately 34% (range: 32-37%). In adult patients who received larotrectinib capsules 100 mg twice daily, Cmax was achieved at about one hour after dosing and steady-state was reached within three days. The mean steady-state Cmax and AUC0-24h of larotrectinib capsules was 788 ng/mL and 4351 ng*h/mL, respectively. In healthy subjects, the AUC of the larotrectinib oral solution was similar to that of the capsules and the Cmax was 36% greater with the oral solution. As compared to a fasted state, the administration of larotrectinib in healthy subjects alongside a high-fat meal resulted in a similar AUC and a reduction in Cmax of 35%.

Following oral administration of a single 100 mg dose of radiolabeled larotrectinib in healthy subjects, 58% (5% unchanged) of the administered radioactivity was recovered in feces and 39% (20% unchanged) was recovered in urine.

Following intravenous administration to healthy subjects, the mean volume of distribution of larotrectinib at steady-state was approximately 48L.

The mean clearance CL/F of larotrectinib is 98 L/h.

応用分野 · 3 件

説明LOXO-101 is an inhibitor of the tropomyosin-related kinases TrkA, TrkB, and TrkC (IC50s = 2-20 nM). It is selective for TrkA, -B, and -C over a panel of 226 kinases at 1 μM. LOXO-101 inhibits the growth of CUTO-3.29, KM12, and MO-91 patient-derived cancer cell lines (IC50s = In vivo, LOXO-101 (60 and 200 mg/kg) reduces tumor growth in a KM12 mouse xenograft model.

説明Larotrectinib, also known as LOXO-101 and ARRY-470, is a small molecule that was designed to block the ATP-binding site of the TRKA, TRKB, and TRKC, serving as a highly specific and potent inhibitor of all of the three tropomyosin kinase receptors.

使用Larotrectinib is a TRK Inhibitor (Tyrosine kinase inhibitor).

上流・下流製品情報

下流製品

ラロトレクチニブ硫酸塩